Morgan Stanley: China Telecom Corporation (00728) underperformed expectations in the fourth quarter of last year with a target price of 5.5 Hong Kong dollars.
Management expects that this year, service revenue, EBITDA, and net profit will maintain stable growth before deducting the impact of value-added tax. Capital expenditure is expected to decrease by 9.2% year-on-year to 73 billion yuan, with computing power capital expenditure expected to increase.
Morgan Stanley released a research report stating that China Telecom Corporation (00728) had service revenue in the fourth quarter of last year that was flat year-on-year at 119 billion RMB (the same below), which was 0.7% lower than expected. EBITDA fell by 5.3% year-on-year to 28 billion RMB, which was 8.2% lower than expected, mainly due to revenue falling short of expectations. Net profit fell by 35% year-on-year to 2.4 billion RMB, which was 36% lower than expected. The annual dividend per share increased by 4.7% year-on-year to 0.272 HKD, with a payout ratio of around 75%. The rating of "synchronized with the market" for China Telecom is maintained, with a target price of 5.5 HKD.
Management indicated that this year, service revenue, EBITDA, and net profit before deducting value-added tax will maintain stable growth. Capex is expected to decrease by 9.2% year-on-year to 73 billion RMB, with capital expenditure on computing power expected to increase. The group sees tokens as the main driver of future growth, benefiting from a strong AIDC infrastructure and computing power. Last year, the platform token consumption reached 1.2 trillion tokens.
Related Articles

IGG (00799) announced its annual performance, with a net profit attributable to shareholders of HK $580 million, and total revenue maintaining steady at HK $5.5 billion.

Shandong Sito Bio-technology (300583.SZ): Methylprednisolone obtains European CEP certificate for chemical raw materials.

Kuaishou-W (01024): Ye Kailin is appointed as Joint Company Secretary and Authorized Representative.
IGG (00799) announced its annual performance, with a net profit attributable to shareholders of HK $580 million, and total revenue maintaining steady at HK $5.5 billion.

Shandong Sito Bio-technology (300583.SZ): Methylprednisolone obtains European CEP certificate for chemical raw materials.

Kuaishou-W (01024): Ye Kailin is appointed as Joint Company Secretary and Authorized Representative.

RECOMMEND

Pace Of Public Fund Issuance Slows, Hong Kong Stocks Become A Primary Focus
24/03/2026

Jensen Huang In‑Depth Interview: Token Economy Surge, AI Computing’s Share Of GDP To Multiply One Hundredfold, NVIDIA’s $10 Trillion Valuation Inevitable
24/03/2026

Are U.S.‑Iran Talks Genuine? At Minimum, Wall Street Read A Clear Signal From Trump’s Five‑Minute Rally
24/03/2026


